2019
DOI: 10.21203/rs.2.10885/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Survival Benefits of Androgen Receptor Signaling-Axis Inhibitor’s at The Cost of Adverse Event Occurrence: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Abstract: Background: Previous evidence directly evaluating the efficacy and safety of the treatment for castration-resistant prostate cancer (CRPC) by androgen receptor (AR) signaling-axis inhibitors was limited by the quantity of randomized controlled trials (RCT) and biased by non-RCTs. We aim to comprehensively assess the efficacy and safety of abiraterone and enzalutamide using only RCTs. Patients and methods: We systematically searched Pubmed, Embase, MEDLINE and ClinicalTrial.gov for RCTs providing data of treatm… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 24 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?